SLC5A2 and heart failure: Notably, various clinical trials have demonstrated a reduced risk of cardiovascular mortality and hospitalization due to heart failure with the administration of SGLT2 inhibitors (Empagliflozin, Canagliflozin, and Dapagliflozin) ([189,190,191]).